Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Vertical Research Upgrades Vulcan Materials to Buy

Vertical Research Upgrades Vulcan Materials to Buy

Vertical Research analyst Michael Dudas upgrades Vulcan Materials (NYSE:VMC) from Hold to Buy.

byBenzinga Newsdesk

September 1, 2022

1 minute read

Vertical Research analyst Michael Dudas upgrades Vulcan Materials (NYSE:VMC) from Hold to Buy.

SEC Chair Gary Gensler Fields Questions On AI, ‘Roaring Kitty’ And Congressional Trading: ‘Disclosure Doesn’t Necessarily Protect A Bad Actor’

By Adam Eckert

June 5, 11:02 AM

Gary Gensler talks AI's role in public markets, recent trading activity in GameStop Corp and insider trading rules in Wednesday CNBC interview.

GME

Analyst Ratings

Breaking Down Uber Technologies: 23 Analysts Share Their Views

By Benzinga Insights

January 30, 9:00 AM

23 analysts have shared their evaluations of Uber Technologies (NYSE:UBER) during the recent three months, expressing a mix…

UBER

Analyst Ratings

Where Arvinas Stands With Analysts

By Benzinga Insights

September 9, 11:11 AM

Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following analyst ratings:

ARVN

Mersana Therapeutics Announces FDA Fast Track Designation Granted To XMT-1660 For The Treatment Of Triple-Negative Breast Cancer

By Benzinga Newsdesk

September 12, 8:20 AM

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical

MRSN

Vertical Research Upgrades Vulcan Materials to Buy

Related Posts

SEC Chair Gary Gensler Fields Questions On AI, ‘Roaring Kitty’ And Congressional Trading: ‘Disclosure Doesn’t Necessarily Protect A Bad Actor’

Breaking Down Uber Technologies: 23 Analysts Share Their Views

Where Arvinas Stands With Analysts

Mersana Therapeutics Announces FDA Fast Track Designation Granted To XMT-1660 For The Treatment Of Triple-Negative Breast Cancer